PRIORITIES FOR FUTURE RESEARCH INTO ASTHMA DIAGNOSTIC TOOLS: A PAN-EU CONSENSUS EXERCISE FROM THE EUROPEAN ASTHMA RESEARCH INNOVATION PARTNERSHIP (EARIP).

<table>
<thead>
<tr>
<th>Journal:</th>
<th>Clinical and Experimental Allergy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manuscript ID:</td>
<td>CEA-2017-0284.R1</td>
</tr>
<tr>
<td>Manuscript Type:</td>
<td>Unsolicited Review</td>
</tr>
<tr>
<td>Date Submitted by the Author:</td>
<td>12-Dec-2017</td>
</tr>
</tbody>
</table>
| Complete List of Authors: | Garcia-Marcos, Luis; Hospital Clinico Universitario Virgen de la Arrixaca, Respiratory and Allergy units; IMIB Research Institute, Paediatrics 
Edwards, Jessica; Asthma UK, Research & Policy 
Kennington, Erika; Asthma UK, Research & Policy 
Aurora, Paul; University College London (UCL) Great Ormond Street Institute of Child Health, 3. Department of Paediatric Respiratory Medicine, Great Ormond Street Hospital for Children, London and Department of Respiratory, Critical Care and Anaesthesia Unit 
Baraldi, Eugenio; University of Padua, Women's and Children's Health Department 
Carraro, Silvia; University of Padova, Women's and Children's Health Dep. 
Gappa, Monika; Marienhospital Wesel, Children's Hospital & Research Institute 
Louis, Renaud; CHU Sart-Tilman, Pneumology 
Moreno-Galdó, Antonio; Hospital Vall d’Hebron & Universitat Autònoma de Barcelona, Department of Respiratory Medicine 
Peroni, Diego; University of Verona, Pediatric section, Dept of Life and Reproduction Sciences 
Pijnenburg, Marielle; Erasmus University Medical Centre/ Sophia Children's Hospital, Paediatrics/ Paediatric respiratory Medicine 
Priftis, Kostas; University Medical School & Attikon General Hospital, Paediatrics 
Sánchez-Solis, Manuel; Hospital Clinico Universitario Virgen de la Arrixaca, Respiratory and Allergy units; IMIB Research Institute, Paediatrics 
Schuster, Antje; Heinrich Heine Universitat Dusseldorf Institut fur Rechtsmedizin, Paediatrics 
Walker, Samantha; Asthma UK, N/A; |
| Keywords: | asthma, omics- and systems biology-, eosinophils |
| Additional Keywords: | Diagnosis, Prediction, Blood marker |
PRIORITIES FOR FUTURE RESEARCH INTO ASTHMA DIAGNOSTIC TOOLS: A PAN-EU CONSENSUS EXERCISE FROM THE EUROPEAN ASTHMA RESEARCH INNOVATION PARTNERSHIP (EARIP).

L. Garcia-Marcos¹, J. Edwards², E. Kennington², P. Aurora³, E. Baraldi⁴, S. Carraro⁴, M. Gappa⁵, R. Louis⁶, A. Moreno-Galdo⁷, D.G. Peroni⁸, M. Pijnenburg⁹, K. N. Priftis¹⁰, M. Sanchez-Solis¹, A. Schuster¹¹, S. Walker² and the EARIP collaboration*

1. Respiratory and Allergy units, Arrixaca University Children’s hospital, University of Murcia & IMIB Research Institute, Murcia, Spain.
2. Asthma UK.
3. Department of Paediatric Respiratory Medicine, Great Ormond Street Hospital for Children, London and Department of Respiratory, Critical Care and Anaesthesia Unit, University College London (UCL) Great Ormond Street Institute of Child Health, London, UK.
4. Women's and Children's Health Department, University of Padua, Padova, Italy.
5. Children’s Hospital & Research Institute, Marienhospital Wesel, Wesel, Germany.
6. Department of Respiratory Medicine, University of Liege, Liege, Belgium.
7. Paediatric Pulmonology Unit, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
8. Department of Clinical and Experimental Medicine, Section of Paediatrics, University of Pisa, Pisa, Italy.
9. Paediatrics/Paediatric Respiratory Medicine, Erasmus MC – Sophia Children’s Hospital, Rotterdam, The Netherlands.
10. Department of Paediatrics, Athens University Medical School, Attikon General Hospital, Athens, Greece.
11. Department of Paediatrics, University Hospital, Düsseldorf, Germany.

Address for correspondence: Luis Garcia-Marcos. Edificio Departamental LAIB, Despacho B2.2.34. Campus Ciencias de la Salud, Avda. Buenavista s/n. 30120 El Palmar. Murcia. Spain. Email: lgmarcos@um.es, Tel: +34868888129, Fax: +34868888127

Funding sources: EU FP7 Grant agreement no: 602077

*listed at the end of the paper.
ABSTRACT

The diagnosis of asthma is currently based on clinical history, physical examination and lung function; and to date there are no accurate objective tests either to confirm the diagnosis or to discriminate between different types of asthma. This consensus exercise reviews the state-of-the-art in asthma diagnosis to identify opportunities for future investment based on the likelihood of their successful development, potential for widespread adoption and their perceived impact on asthma patients.

Using a two-stage e-Delphi process and a summarising workshop, a group of European asthma experts including health professionals, researchers, people with asthma and industry representatives ranked the potential impact of research investment in each technique or tool for asthma diagnosis and monitoring. After a systematic review of the literature, 21 statements were extracted and were subject of the two-stage Delphi process. Eleven statements were scored 3 or more and were further discussed and ranked in a face to face workshop.

The three most important diagnostic/predictive tools ranked were: “New biological markers of asthma (e.g. genomics, proteomics and metabolomics) as a tool for diagnosis and/or monitoring”, “Prediction of future asthma in preschool children with reasonable accuracy” and “Tools to measure volatile organic compounds (VOCs) in exhaled breath”.

KEY WORDS: Asthma; Diagnosis; Prediction; Blood marker; Exhaled breath condensate; FeNO; Lung function tests; Multiple breath washout.
INTRODUCTION

The European Commission launched the European Innovative Partnerships (EIPs) in the FP7 program as a way of shortening the process from the initiation of research to the marketing of the findings, whenever possible, in all kinds of fields. According to the EU Commission, “EIPs act across the whole research and innovation chain, bringing together all relevant actors at EU, national and regional levels in order to: 1. step up research and development efforts; 2. coordinate investments in demonstration and pilots; 3. anticipate and fast-track any necessary regulation and standards; and 4. mobilise ‘demand’ in particular through better coordinated public procurement to ensure that any breakthroughs are quickly brought to market”. In accord with this philosophy, Asthma UK applied for an EIP for asthma and constituted the European Asthma Research Innovative Partnership (EARIP) with the aim of producing a European roadmap to quickly, effectively and drastically reduce asthma morbidity and mortality, and to look for the eventual prevention and cure of asthma.

Led by Asthma UK, EARIP gathered a considerable number of stakeholders from health professionals, patient associations and pharmaceutical companies. The project was divided into different work packages, including one on diagnostic tools. In the present consensus statement, we present the asthma diagnostic tools on which stakeholders agreed warranted future investment.

The group, with external consultation, agreed on a list of relevant topics (Table 1), which constitute the different topics of the systematic review presented wherein. Working group members performed literature searches based on expertise and knowledge in this area (Table S1). The framework shown in table 2 was applied to each topic in order to perform a short and focused review, providing up-to-date, in-depth
information on each topic, to provide the base for consensus prioritisation and ranking.

A first general literature search was carried out between Jan 2015 and March 2015. After a first report was written and the Delphi exercise was ended up, a new search in order to update the review was made between September 2016 and March 2017.

STRUCTURED REVIEW

1. Introduction

With no single genetic or environmental cause, asthma is difficult to define. The diagnosis of asthma is a clinical one, and should be based on the history of characteristic symptom patterns and evidence of variable airflow limitation; however, symptoms do not correlate very well with other hallmarks of asthma such as variable airway obstruction, airway hyper-responsiveness and chronic inflammation; it is unclear how all these features relate to each other. It is unknown if and how these features should be used in the diagnosis and monitoring of asthma.

Several diagnostic tests exist, the sensitivity and specificity of which are not as high as would be desired, thus diagnosis can be considered a mosaic of many pieces including tests of lung function, tests for inflammatory markers, as well as patterns of characteristic symptoms and signs in a clinical history. A further problem is the lack of standardisation of existing diagnostic tests, and in particular their applicability or even usability in young children.

As we become more knowledgeable about the different asthma phenotypes there is a desperate need for new diagnostic tools to prevent over-, under-diagnosis and over-, under-treatment of patients to reduce asthma morbidity and mortality.

2. Inflammatory markers and cells
2.1 Blood

Eosinophilic inflammation is a hallmark in the vast majority of schoolchildren with asthma. Blood for measuring eosinophils and markers of eosinophilic inflammation is easy to obtain and may therefore be suitable for diagnosis and monitoring of asthma in children and adolescents. A differential cell count will give numbers for eosinophilic granulocytes. Eosinophil cationic protein (ECP) is a molecule that is released from activated eosinophils. Periostin is a protein secreted by airway epithelial cells and lung fibroblasts in response to IL-4/IL-13 which are key mediators of TH2-driven asthmatic inflammation.

Some further possible biomarkers of TH2-mediated asthma are currently being investigated: YKL-40, osteopontin, eosinophil-derived neurotoxin, and some metabolites (choline, arginine, acetone, protectin D1); however, existing data need to be validated and their usefulness for clinical practice remains to be elucidated (1).

2.1.1 Eosinophils and Eosinophil Cationic Protein

Eosinophils can be easily measured in peripheral blood, but may be of use only when asthma is eosinophilic, which is not necessarily the case, especially in adult patients. Blood eosinophils >4% increase the probability that recurrent wheeze in combination with other risk factors in a child is asthma (2). Although being significant, the correlation between blood and sputum eosinophils is far from perfect (3). Setting the abnormal threshold of blood and sputum eosinophils at 400/µl and 3% respectively, a discrepancy was found in 32% in a large asthma cohort, the group with high sputum eosinophils but normal blood eosinophil count representing 25% of the patients (4).

Even though studies have confirmed the association of ECP with allergic asthma, ECP determination does not appear to be a valuable diagnostic marker of asthma, as changes in serum ECP concentrations can also be found in other atopic
diseases such as allergic rhinitis, and even in conditions not related to allergic inflammation such as bacterial sinusitis (5). Determination of ECP concentration has been discussed for assessing the severity of asthma, particularly in children, but it has not evolved as a helpful marker of inflammation in clinical practice.

In summary, blood eosinophils may play a role in the diagnosis of eosinophilic asthma, and have a value in risk-assessment and response to treatment. In addition, as the correlation between airway eosinophilia and blood eosinophilia is low, the differential role in subendotypes will have to be better defined. There does not seem to be an advantage for measuring ECP compared to the absolute eosinophil count.

### 2.1.2 Periostin

Periostin appeared to be a good systemic biomarker of TH2-driven or eosinophil airway inflammation in adults (6). However, expectations about the usefulness of periostin to diagnose asthma have not been fulfilled as it is increased during growth and can be also be elevated in many inflammatory processes (7)

### 2.2 Exhaled breath

#### 2.2.1 Fractional exhaled Nitric Oxide (FeNO) in asthma diagnosis and monitoring

##### 2.2.1.1 Asthma Diagnosis

Exhaled nitric oxide is a user-friendly biomarker which has become increasingly popular among clinicians. While first measured online by chemo luminescence with fixed machine it can now be measured with a portable electrochemistry system. As FeNO value is flow sensitive it is important to standardize the flow rate at which the measure is performed. It has become accepted that FeNO is best measured at a flow rate of 50 ml/sec (8).

Early studies found that patients with asthma displayed raised level of FeNO in their exhaled breath compared to healthy subjects. Treatment with ICS results in a
dramatic reduction in the level of FeNO (9). Current smoking also causes a sharp reduction in measured values (10). Median values of FeNO in large asthma cohort studies were found to range between 25 and 35 ppb (10,11). Several studies have investigated the use of FeNO to make an asthma diagnosis. A threshold value of 20 ppb combined to symptom was proposed as a tool for asthma diagnosis that was superior to the measurement of the fluctuations of peak expiratory flow rate in mild to moderate asthmatics. This threshold was probably too low and more recent studies in patients with symptoms of asthma and normal baseline FEV1 value or no significant bronchodilation has shown that FeNO threshold of 34 ppb (at the flow rate of 50 ml/sec) yielded the best compromise for an asthma diagnosis with a high positive predictive value but a low negative predictive value (12).

While it was initially thought that elevated FeNO was a key marker of asthma in general it later appeared that FeNO was mainly reflecting the presence of eosinophilic airway inflammation (10). Therefore elevated FeNO is assumed to reflect an eosinophilic asthma phenotype, which account for approximately 50% of all asthmatics seen in clinical practice although higher in children (4,13,14). The threshold values that predict eosinophilic inflammation varies according to the dose of ICS, the smoking status and atopy (10). Combining FeNO and peripheral eosinophil counts seems to be a better approach than just using FeNO values (15). However, it should be always be kept in mind that asthma cannot be ruled out when symptoms are compatible with the condition despite low values of FeNO, as asthma is not necessarily eosinophilic (16,17).

2.2.1.2 Asthma monitoring

FeNO has been proposed as a biomarker that may help the clinician to manage asthma (18,19). FeNO values above 33 ppb in one study (20) and above 47 ppb in
another (21) were found to predict a good clinical response to ICS in patients with chronic respiratory symptoms. This is in line with the observation that only eosinophilic asthma convincingly respond to inhaled corticoids and add to the importance of asthma phenotyping in clinics (22).

The utility of using FeNO to adjust the dose of ICS to reduce exacerbations in asthmatics already receiving treatment has been investigated in several studies with controversial results (23,24). In this setting FeNO seems to perform less well that sputum eosinophils. However thresholds to adjust the dose of ICS may not have been chosen adequately in some of those trials (25).

Accuracy of FeNO measurement is firmly established and it is recognised that elevated value reflects an eosinophilic phenotype and predict good response to ICS (18). There is a need to study the cost effectiveness of FeNO as a tool for asthma diagnosis and choice of treatment in a large scale cohort study.

2.2.2 Volatile organic compounds (VOCs)

Assessing VOCs using electrosensor (eNose) and, even better, qualifying and measuring them using mass spectrometry has great potential but to date has only been done in a limited series in research settings (26). This has been done to distinguish asthmatic lungs from those normal ones, but no study has been yet published which has assessed the measurements of VOCs to monitor asthma treatment, although one study used VOCs to predict exacerbations in children with reasonable accuracy (27).

Further exploring the value of VOCs to assist phenotyping asthma and predicting major clinical outcomes such as exacerbations and response to treatment would be of great interest.

2.2.3 Markers in breath condensate
Exhaled breath condensate (EBC) enables the study of the pathological processes undergoing in the lung (28). As EBC is a non invasive technique it can be easily applied even in children too young to be able to perform other tests. In EBC several molecules have been studied that may have a role as biomarkers in asthma.

Many studies have investigated the role of eicosanoids in asthma. The presence of these mediators in EBC has been documented using both immunoassays and reference analytical techniques. Increased levels of LTB4, a potent inflammatory mediator, have been demonstrated in steroid naïve children (29) and adults (30) with asthma. Likewise, increased levels of cysteinyl leukotrienes, which are powerful broncho-constrictors and pro-inflammatory mediators, have been reported in both children and adults, with the highest concentrations found in subjects with severe asthma, despite ongoing ICS therapy (31,32).

Beside leukotrienes, which are 5-lipoxygenase metabolites, increased levels of other inflammatory metabolites of the 15-lipoxygenase pathway such as eoxins, have been reported in asthmatic children (33). Interestingly, the simultaneous assessment of a set of metabolites of arachidonic acid led to the identification of a profile of eicosanoids (including prostaglandins and leukotrienes) capable of discriminating asthmatic and healthy children with high accuracy (34).

Several markers of oxidative stress have also been studied in EBC, pointing to an increased oxidative burst in asthmatic airways. 8-isoprostan and hydrogen peroxide (H2O2) are the oxidative stress biomarkers better studied in EBC. 8-isoprostan is a product of arachidonic acid peroxidation. High levels of this mediator have been found in asthma, and, in particular, in subjects with problematic asthma, suggesting that oxidative stress may play a role in the pathogenesis of this asthma phenotype (31,35,36).
$\text{H}_2\text{O}_2$ belongs to reactive oxygen species (ROS) deriving from the dismutation of superoxide anions. A meta-analysis conducted on eight studies analyzing the role of EBC $\text{H}_2\text{O}_2$ in asthma demonstrated that this biomarker is increased in adults with asthma, shows a trend toward a correlation with the degree of asthma severity and control and it seems sensitive to corticosteroid treatment (37). Similar results were found in children (38). These features suggest a possible role of this biomarker in the follow-up of asthmatic patients. Noteworthy, the measurement of oxidative stress biomarkers in EBC may help in the identification of asthmatic subjects with higher oxidative stress, who may likely benefit from the development of novel anti-oxidant treatments.

EBC pH is a robust marker, with a good reproducibility (39,40). Reduced EBC pH has been reported in both adults and children with asthma (41). In particular, a significant reduction of PH of the airways has been reported during acute asthma exacerbations (36,42,43). Nonetheless in the epidemiological setting EBC pH could not discriminate between asthmatic and healthy subjects (44). In a large cohort of subjects with severe and non-severe asthma, EBC pH turned out to be on the whole normal, but there was a subgroup of asthmatic subjects with very low EBC pH (<6.5) (45). EBC pH may be a useful biomarker in the characterization of a specific asthma sub-phenotype.

Increased levels of adenosine have been found in the EBC of asthmatic children and adults (46). Using multiplex immunoassay technology, increased levels of cytokines, chemokines and soluble adhesion molecules have been reported in children with asthma and also in preschool children found to have persistent wheezing at 5 years of age (47-49). Eventually, increased levels of the inflammatory and oxidative stress mediator ADMA (asymmetric dimethylarginine) have been showed in EBC from asthmatic children (50).
The EBC technology has a significant potential for asthma diagnosis and monitoring, but the technique needs to be better standardized if we want to move it from research to clinical practice. Investments are urgently needed to achieve a full standardization of the methodologies used for sample collection and analysis.

### 2.3 Sputum and bronchoalveolar lavage.

Ideally, any material obtained directly from the lower airways of asthmatic patients could be very useful diagnostic biomarker. A *large number of studies* have been conducted over the last decades to evaluate the diagnostic utility of sputum and *bronchoalveolar lavage* (BAL). Sputum samples collection is not always a simple procedure, especially in children and BAL is an invasive technique (51,52).

#### 2.3.1 Sputum

Studies on sputum look mainly at the potential informative role of sputum as a material with airway inflammatory biomarkers. Most studies have focused on asthma severity assessment and provision of more efficient *biomarker-guided treatment* (53-55).

The technique of induced sputum that allows to collect airway secretion after inhalation of saline is valuable in approximately 80% of the patients and has been key in the emergence of the concept of inflammatory phenotype (56). Sputum eosinophil count, neutrophils, and several soluble mediators -most recently periostin- have been examined (54). They are considered as the only non-invasive measure of airway inflammation that has a clearly proven utility in clinical practice in adults (56). Recent studies have further highlighted the role of sputum eosinophils in poor asthma control. A retrospective study on a large asthma cohort has shown that patients combining sputum eosinophil > 3% and blood eosinophil counts > 400/µl have poor asthma control and are prone to exacerbate (4). In a prospective study conducted in severe asthmatics
uncontrolled despite high dose of ICS and LABA, the repeated presence of eosinophils in the sputum was associated with increased of exacerbations (57). Furthermore in a large retrospective cohort of asthmatics it has been shown that both fluctuation in FEV1 and fluctuation in sputum in sputum eosinophils independently correlated with change n ACQ6 (58). Sputum induction can be effectively performed in adults, but there might be difficulty in collecting sufficient sputum in children under 8 years (51,56). Furthermore, one study in children using sputum eosinophils for monitoring asthma was negative (53).

More studies are needed to clarify the biomarker (or combination of biomarkers) that could be most valuable in practice as a tool in precision medicine.

2.3.2 Bronchoalveolar lavage (BAL)

BAL is a major tool in the diagnostic procedure for a number of pulmonary diseases, including asthma. It can provide useful information about the pattern of airway inflammation in terms of total cellularity, differential cell profile and several inflammatory mediators (59,60). However, the information available is fragmentary, as most of the studies look at either refractory asthma or certain biomarkers from patients in whom bronchoscopy could be justified and suffer from lack of specificity (59,61). Subsequently, these studies are affected by methodological difficulties and selection bias, with patients having sufficiently severe disease to justify an invasive sampling procedure. Data interpretation arising from such studies need special caution. BAL has also been used for specific asthma phenotypes identification (61).

Because of the invasive nature of fiberoptic bronchoscopy, BAL could be used in certain patients only. It is still useful for difficult asthma to detect other implicated causes of symptoms such as silent aspiration or persistent bacterial infection or congenital abnormalities (children).
2.4 Systems biology

In the study of chronic complex diseases, such as asthma, beside the assessment of individual biomarkers, it is of utmost importance to study several mediators simultaneously, through a systems biology approach. An overall profile can better mirror the complexity of asthma, in the pathogenesis of which a large number of cell types and molecular pathways contribute, interacting in complex networks (62,63).

The ‘-omic’ technologies (genomics, proteomics and metabolomics) are systems biology platforms. Being guided by no a priori assumptions, they look into which components are associated with a given pathological condition, shedding light on pathogenic pathways and phenotypic characteristics with a hypothesis-generating approach (63).

The ‘-omic’ technologies, proteomics and metabolomics in particular, have been applied in the study of asthma. The proteomic analysis of EBC proved that it is possible to identify profiles of differentially expressed proteins, capable of discriminating asthmatic children from healthy controls (64).

The metabolomics approach has been applied to several biofluids. In adults the metabolomics analysis of serum (65) and exhaled breath condensate (66) samples demonstrated a clear separation between asthmatic and healthy subjects. Moreover, the metabolomics analysis of urine samples showed that during an acute exacerbation a profound alteration of the metabolic profile occurs, with a significant role of the metabolites indicative of oxidative stress (67).

In children, metabolomic analysis of both urine and EBC samples proved capable of clearly discriminating between healthy and asthmatic children (68,69). Metabolomics has been also applied in the characterization of different asthma phenotypes and a separate metabolic profile has been demonstrated in children with
severe asthma by applying the metabolomics approach either to plasma (70) or to EBC (50) samples.

An ‘-omic’ approach has been applied also to the study of volatile organic compounds (VOCs) in exhaled breath. The VOCs profile could discriminate asthmatic from healthy children (48). In addition the study of VOCs profile seems to have promising application for the prediction of asthma exacerbation (27) and for the early identification of asthmatic children among preschool children with recurrent wheezing (71).

The ‘-omic’ technologies may have a key role in the development of personalized medicine, potentially contributing to shift the focus of medicine from the traditional symptom-oriented diagnosis and treatment of diseases (reactive medicine) towards the so-called ‘P4’ medicine, which concentrates on preserving health through the prevention and early diagnosis of disease (72).

The ‘-omic’ technologies, in fact, enabling the simultaneous assessment of several mediators can lead to the discovery of early diagnostic profiles and can shed light on new, sometimes unexpected, biomarkers that may be applied to monitor asthma and to guide therapy.

3. Lung function tests

3.1 Cooperative patients

3.1.1 Spirometry

Asthma diagnosis should be based on both the presence of symptoms and objective demonstration of variable airflow obstruction. However, there may be important barriers to performing lung function tests not only in primary care settings but also in secondary care settings (73,74). Some studies showed that spirometry has been used in diagnosis in only 21-25% of pediatric asthma patients in a primary care setting
(75,76). The correct use of spirometric measurement is crucial for an accurate diagnosis.

This may result in both over-diagnosis and under-diagnosis of asthma (74). One third of adults individuals with physician-diagnosed asthma may not have asthma when objectively assessed (77). Spirometry is an objective tool that may help to prevent misclassification of asthma severity and inappropriate underuse or overuse of asthma medication among paediatric asthma patients: nearly one third of patients had their treatment plans changed after clinicians viewed their spirometry results (78).

Spirometry is normal in many patients with asthma at the time of clinical presentation, and objective confirmation of variable airflow obstruction may be challenging. Most adults in primary care have mild asthma and well preserved lung function. Airflow obstruction defined as a ratio of FEV₁/FVC < 70% was found only in 21% adult patients diagnosed with asthma in a primary care setting (79) but this proportion raises to 60% in severe adult asthmatics despite treatment with high dose ICS/LABA (80). Most asthmatic children also have a normal spirometry, with 94.2% of 3,626 children having a FEV₁ > 80% predicted (81) and only 10.5% of 3,612 asthmatic children having a FEV₁/FVC < 80% (82). In this study FEV₁/FVC < 80% had a high sensitivity for asthma diagnosis (> 90%) but low specificity (< 20%), being associated with asthma diagnosis in patient with concomitant allergic rhinitis but not in children without allergic rhinitis.

A fixed limit FEV₁/FVC ratio (< 70% in adults) is often used to identify airflow obstruction instead of the lower limit of normal (<5<sup>th</sup> percentile) (83). This fixed cut-off points have been shown to cause a lot of misidentification of airflow obstruction specially in young adults, increasing the likelihood of under diagnosis of obstruction (84). The use of Z-scores in children is probably more appropriate.
A decreased FEF_{25-75%} is indicative of small airway obstruction. The utility of an isolated decrease in FEF_{25-75%} in the setting of otherwise normal spirometry is unclear, because values are more variables than FEV\textsubscript{1}. Evidence suggests than a reduced FEF\textsubscript{25-75%} correlates with bronchial hyperresponsiveness on bronchoprovocation testing (85,86).

The utility and limitations of spirometry in asthma diagnosis are well established. A wider use of this technique in primary care with implementation of new algorithms will allow a better diagnostic classification of both pediatrics and adult patients. However, there is no single randomised control trial showing that guiding treatment on FEV1 improves asthma outcomes.

3.1.2 Plethysmography and asthma diagnosis

Plethysmographic measurement of lung volumes does not provide much additional information for clinical decision making in most patients with asthma and it is not recommended in current guidelines.

Lung hyperinflation is frequent in uncontrolled asthma, and a significant proportion of both children and adult asthmatic patients have elevated residual volume and abnormal RV/TLC ratio in the presence of normal FEV\textsubscript{1}/FVC ratio and absence of significant bronchodilator response (87,88). The clinical significance of these findings in asthma needs further prospective studies. In adults the role of airway resistance (Raw) and specific airway conductance (sGAW) as an aid to asthma diagnosis has been explored in a real life study and found to predict disease with a positive predictive value around 75% but a poor sensitivity (89).

Measurement of specific airway resistance (sRaw) using plethysmography could be useful. In epidemiological studies as early as age 3 years, sRaw differs between children with a history of wheezing and those without (90), and higher sRaw at age 3
years is associated with subsequent persistence of wheezing (91). sRaw seems to be also adequate to assess bronchodilator response in children (92). However in some studies the use of sRaw in schoolchildren have not been adequate to diagnose asthma, because of high variability and huge overlap between healthy children and those with asthma (82).

In summary, the value of plethysmography in asthma diagnosis is very limited, with sRaw having some role.

3.2 Non-cooperative patients

Diagnosing asthma in pre-school children is often challenging (93). The demonstration of bronchial reversibility after administration of a bronchodilator, help clinicians to establish the appropriate treatment. Unfortunately, in this age group spirometry is often not applicable because results depend on effort and effective co-operation by patients. Therefore, non-invasive lung function measurements requiring only passive co-operation, while the patient is breathing at normal tidal volume, such as impulse oscillometry, the forced oscillation technique, and interrupter technique have been proposed (94).

3.2.1 Impulse oscillometry and forced oscillation technique

Impulse oscillometry (IOS) measures the resistance and resonance capacitance of the lungs, both at small and large airway level, performing measurements in a noninvasive, effort-independent manner during spontaneous breathing. The most relevant outcomes of IOS are R5, the resistance in small airways, R15 or higher, the resistance in larger airways and the low frequency integrated impedance reactance at R5 (94,95). All these measurements can be compared to baseline following bronchodilator or longitudinally in patients with chronic asthma that require regular treatment (95).
IOS could be a more sensitive method to evaluate small airway than spirometry parameters such as FEF 25-75, because, in contrast with spirometry that requires a deep inspiration, forced oscillation technique (FOT) does not modify the airway smooth muscle tone (95).

It has been shown that IOS provides effective measures of lung dysfunction in 4-year-old children at high risk for persistent asthma (96). This was confirmed and extended in another study evaluating at this age range the effects of short and long acting bronchodilators (97). More recent studies demonstrated the efficacy of IOS as an alternative to FEV1 in older asthmatic children (98,99). Interestingly it has been shown that R5 but not FEV1 showed improvement in patients with persistent asthma after inhaled steroid treatment (100).

FOT holds the perspective of improving the diagnosis of airway obstruction, quantifying the amount of airway reversibility and hyperactivity even in non-collaborative patients.

IOS practice requires well trained technicians and physicians both for performing and evaluating the tests. Pitfalls of IOS are airway leak and poor holding of the cheeks, as well as tongue effect, cough, swallowing, shallow breaths and vocalization, with a significant influence of the upper airway shunt in preschool children.

Normal values of respiratory impedance (Zrs) for preschool children have been obtained, as well as of respiratory resistance (Rrs) (101-103). However, there is a lack of standardization in measuring procedures and equipments.

3.2.2 The interrupter technique

The interrupter technique is able to detect changes in airway caliber (104). The principles of the interrupter technique are that, during a sudden and rapid airflow
interruption at the mouth, the alveolar and mouth pressure will equilibrate. The interrupter resistance (Rint) is defined as this pressure divided by the airflow measured immediately before interruption (105).

There are reference values for preschool children, which are difficult to compare being often obtained using different methods. The technique is able to measure the magnitude of changes in airway caliber after inhalation of a bronchodilator, but the cut-off value for a decrease in Rint beyond which a response may be considered clinically effective remains to be established (94,104,105).

To make the technique more reproducible and uniform between centers a series of recommendations have been presented (94). However, many issues remain to be clarified, particularly to establish the cut-off values beyond which a clinical response to bronchodilator could be considered clinically relevant.

3.2.3 Lung function tests in infants and asthma

Cohort studies have shown that those infants who develop asthma, could have, prior to any respiratory illness, impaired lung function. This premorbid condition has been described in different asthma phenotypes (106-109). Considering infant lung function before the first episode of wheeze and the subsequent development of atopy during the first 6 years of life, three phenotypes have been described: transient wheezers, who have low neonatal lung function, do not develop atopy and maintain lung function during childhood, suggesting a small or malacic airway (106); persistent wheezers, who have premorbid normal or decreased lung function (according to the Tucson cohort (106) or the Copenhagen cohort (107) studies, respectively), do develop atopy, and lung function decreases during the first years of life, suggesting airway remodelling very early in life; finally, late onset wheezers have normal neonatal lung function, and although they develop atopy their lung function is maintained (106-108).
However, there are some limitations in those studies: most based their observations on very limited number of cases (106,108,109); and although one (107) assessed 311 cases all mothers had a history of doctor’s diagnosis of asthma after age 7. Moreover, the techniques to assess lung function are different between studies (VmaxFRC, FEV0.4, and FEV0.5). Furthermore, there is a significant overlap of lung function values in infants between those with and without future asthma and between different asthma phenotypes. On the other hand, regression equations based on data from 429 healthy infants aged 4-118 weeks has been published very recently (110).

It is essential to have adequate normal population-based reference values of infant lung function. Normal lung function values of raised-volume-rapid-thoracic-compression technique, for instance, are based on only 155 tests (111), and on top of that it is mandatory to correct the regression equations of normality if the most extended equipment in Europe is used (112), not to speak of different ethnicities.

If decreased lung function very early in life, or even in utero, plays any role in the development of asthma, we need to understand how and why this decrease is produced in order to design strategies to prevent it. Thus, it is important to study prenatal risk and protective factors (other than the known ones, such as prematurity and tobacco smoke exposure) related with lower lung function very early in life. And although we have some clues in infants born from high risk mothers (113), research should be extended to the whole population.

3.2.4 Inert gas washout for measurement of ventilation inhomogeneity

The majority of lung function tests measure flow; airway resistance; or lung volumes. Whilst such measures are undeniably helpful, one of the greatest contributions to impaired respiratory function in asthma is the effectiveness of gas mixing or ventilation distribution. We know that ventilation distribution has some degree of
heterogeneity in healthy individuals is more pronounced those with stable airways
disease; and that this situation can lead to catastrophic shifts - in turn leading to
hypoxaemia - during bronchoconstriction (114). There is therefore increasing interest in
the objective monitoring of ventilation heterogeneity in both stable and unstable asthma,
and the most promising tools for this are inert gas washout tests.

These investigations rely upon measurement of exhaled inert gas (either
nitrogen, or a previously inhaled gas such as sulphur hexafluoride) during multiple
breath or single breath washout (MBW or SBW). The former test usually employs tidal
breathing, and produces indices of overall ventilation heterogeneity such as the lung
clearance index (LCI), or mechanism dependent indices such as $S_{\text{cond}}$ and $S_{\text{acin}}$, which
broadly measure conducting airway generated heterogeneity and more peripherally
generated heterogeneity respectively (115). SBW usually employs a raised volume
inspiration and expiration, and the phase III slope of the expiration is analysed.
Performing SBW using multiple inert gases of differing molecular weight and therefore
diffusivity can provide additional information as to where in the airway tree changes in
airway calibre are likely to be occurring (116,117).

Calculation of the $S_{\text{cond}}$ and $S_{\text{acin}}$ indices from MBW has demonstrated that
proximal conducting airways and more peripheral airways generate heterogeneity in
subjects with asthma, and that both mechanisms are partly but not wholly reversed by
bronchodilator (115,118,119). Intriguingly, the degree of baseline heterogeneity appears
to predict severity of airway hyperresponsiveness in adults and children with asthma
(120-122), in a way that differs from subjects with COPD (123). One possible
explanation is that baseline heterogeneity is predictive of airway closure during
bronchoconstriction (114,124). Further studies have identified relationships between
heterogeneity and symptom control (125); clinical stability (118); and response to
inhaled corticosteroids (126). The link between heterogeneity and inflammation, as measured by exhaled nitric oxide, is not clear, like with most lung function tests (121,122,127). There are limited data relating heterogeneity to asthma phenotype, though one study in children with preschool wheeze has identified $S_{\text{cond}}$ as an excellent discriminator between the episodic viral wheeze and multitrigger wheeze phenotypes (128), although those phenotypes have not been shown to be very stable over time (129). It is noted that the majority of studies utilising MBW have employed the $S_{\text{cond}}$ and $S_{\text{acin}}$ indices. Global indices such as LCI are widely used in the study of CF lung disease and in bronchopulmonary dysplasia, but how LCI relates to $S_{\text{cond}}$ and $S_{\text{acin}}$ in asthma is not well understood (128,130,131).

The SBW test is quicker and more straightforward to perform and interpret than MBW, and some of the earliest studies investigating ventilation heterogeneity in asthma and COPD used this method (132-134). These studies identified links between asthma diagnosis and severity and the Phase III slope from SBW. More recent studies have confirmed these findings (135), and have utilised multiple gases to localise presumed bronchoconstriction (116,117,136).

The field is new, and not yet well understood. However the use of MBW is in the process of transforming the monitoring and care of early/mild CF lung disease, and the promising early data in subjects with asthma should not be ignored. It is possible that inert gas washout tests could prove to have advantages over more traditional lung function tests in asthma monitoring, particularly given that ventilation heterogeneity is known to be present at baseline, and to lead to dramatic changes in ventilation distribution during bronchoconstriction. An additional, crucial advantage is that most inert gas washout measurements can be collected during tidal breathing, and can
therefore be performed in infants; preschool children; and older subjects who are unable
to co-operate with more traditional lung function tests.

At present, the MBW technique is too complex and time-consuming to be
employed in routine asthma monitoring but will continue to be researched to better
understand asthma phenotyping and physiology. In the longer term the development of
tidal breathing SBW, possibly utilising multiple inert gases, could become a valuable
clinical tool. There is more than one approach to develop such a test, but it is noted that
a multiple gas method has already been used to identify peripherally generated
heterogeneity in children with mild asthma symptoms and normal spirometry (136).

3.3. Bronchodilation

The diagnosis of asthma should be based on the history of characteristic
symptom patterns and evidence of variable airflow limitation (83). As the GINA
guidelines point out, evidence of variable airflow limitation should be documented from
bronchodilator reversibility testing or other tests. Hence, tests of airflow obstruction and
airway responsiveness (including reversibility testing) may provide support for the
diagnosis of asthma in children and in adults. In patients with normal or near-normal
pre-treatment lung function, reversibility testing with a bronchodilator is of limited
value, as there may be little room for measurable improvement (83). However, should
still be performed, in particular in children who may have supranormal values. In
contrast, in cases of established airflow obstruction upon initial assessment, measuring
the bronchodilator response to β2-agonists appears helpful to demonstrate variability of
airflow limitation. A significant increase in airflow (as determined by FEV1 or FVC or
PEF, depending on the protocol employed) after administration of a bronchodilator
indicates reversibility of airflow obstruction and supports the diagnosis of asthma
(83,137).
There is no consensus about the drug, dose or mode of administering the bronchodilator in the lung function laboratory. Current guidelines recommend inhalation of 100-400 µg (children) and 200-400 µg (adults) salbutamol or equivalent (83,83). As an alternative to measuring the immediate response to a bronchodilator in the lung function lab, it is also recommended by some guidelines to test the response to 2-8 weeks of a therapeutic trial with inhaled corticosteroids (ICS). Also, there is no clear consensus about which degree of lung function improvement constitutes significant reversibility in subjects with airflow obstruction (137). There is as yet no consensus on how a bronchodilator response should be expressed (percent of initial spirometric value, or percent of predicted value, or absolute change), and which variables should be used (FEV1, FVC, PEF). These differences are due to the heterogeneity of study designs and results, and also due to different interpretations of the outcomes of these studies that have been conducted in the general population and in patient populations (studies referenced by (137)). Also, the bronchodilator response tends to increase with decreasing baseline FEV1 (138). So, upon establishment of a generally applicable guideline, decisions will always be well-founded, but nonetheless the definition of a universal cut-off level for a “positive” bronchodilator response will finally be arbitrary. Increments of lung function parameters of <8% are likely to lie within the range of measurement variability (137,139,140). The recent 2017 GINA guidelines indicate the following criteria for making the diagnosis of asthma: For adults an increase in FEV1 of >12% and >200 ml from baseline, and for children an increase in FEV1 >12% predicted. The ATS/ERS task force on standardization of lung function testing considers post-bronchodilator FEV1 or FVC >12% and 200 ml compared with baseline as “significant“ bronchodilation (137).
Even though international recommendations regarding reversibility testing do differ in various aspects, knowledge of the ATS/ERS task force suggestions appears useful as this proposal has been set up to help minimise differences within and between laboratories. Beyond numerical criteria, it also appears useful in clinical practice to judge and compare the shapes of the flow-volume curves before and after bronchodilator inhalation.

A large world-wide study on the bronchodilator response in adult healthy general populations recently reaffirmed the 12% criterion (141) which approximates the 95th percentile for percentage change in FEV1 after bronchodilator inhalation in general population studies mainly consisting of adults (142). Still, the recommendations of the ATS/ERS task force have very recently been a subject of animated scientific debate (143-146). In any case, sensitivity and specificity of the bronchodilator response for the diagnosis of asthma are limited. One major problem in judging reversibility tests in diagnosis of adult asthma is the fact that there is also a significant bronchodilator response in COPD (147). Patients with asthma may tend to show a larger increase in flow and volume after inhalation of a bronchodilator than COPD patients (137), and a \( >400 \text{ml} \) improvement in FEV1 in response to a bronchodilator is considered to strongly suggest underlying asthma (83). However, the response to a bronchodilator has never been shown to add to the differential diagnosis, and the Global Initiative for Chronic Obstructive Lung Disease recommends that the degree to which airflow is reversible should not be used as a criterion in making the differential diagnosis between asthma and COPD (148).

In children, diseases other than asthma may be associated with significant bronchodilator responses, such as allergic rhinitis and bronchopulmonary dysplasia (149). On the other hand, also in children, an absent response to bronchodilators does
not exclude asthma (150). If the bronchodilator test is positive, it has been shown in children that this is predictive of a good response to ICS (151). However, as most children with asthma have baseline FEV1 within the normal range (152), the diagnostic value of bronchodilator responses during stable disease may often be limited in this age group. Different cut-off values have been proposed for the pediatric age group in order to increase sensitivity and specificity of bronchodilator response tests. The most recent of these studies on the validity of current criteria of a significant bronchodilator response included a large cohort of 1041 children with mild-to moderate asthma from the US Childhood Asthma Management Program (CAMP) that were compared to 250 control subjects. Here, the conventional “adult” cut-off of 12% improvement in absolute FEV1 was associated with a good specificity for asthma diagnosis of 89.5%, but with a poor sensitivity of 35.6% (153). This poor sensitivity may be due to the fact that only a minority of CAMP children had a baseline FEV1 of <80% predicted. Even though a cut-off of 8% resulted in a better sensitivity (54.4%), the authors do not recommend to choose a lower specific general cut-off criterion, given the variability of this test in children.

To summarize, the bronchodilator response test is one of the pieces in the mosaic of diagnosing asthma, along with a characteristic pattern of symptoms and signs in clinical history, and maybe signs of inflammation, such as increased FeNO. With baseline lung function showing an obstructive pattern, serial monitoring, such as serial peak flow readings may be useful for demonstrating variation and variability of airflow limitation. With normal baseline lung function, the bronchodilator response test is less valuable, and other tests like bronchoprovocation tests appear more expedient.

In children participating in the CAMP study it has been shown that a consistent bronchodilator response of >10% over 4 years predicted night-time awakenings, oral
steroid bursts, hospital visits, and missed days of school (154). Accordingly, in long
term asthma management, a positive bronchodilator response may indicate the need for
an intensification in asthma treatment, e.g. by adding a long-acting bronchodilating
agent to an ICS or increasing the ICS dose (155,156).

3.4 Bronchial challenge tests

Fluctuation in airway calibre, a critical feature of asthma can be demonstrated in
several ways including significant bronchodilation to $\beta_2$ agonists and
hyperresponsiveness towards direct stimulating agents like methacholine and histamine.
When significant reversibility to inhaled salbutamol is not demonstrated, bronchial
challenge with a direct agonist of smooth muscle is essential. The common way to
express the bronchial hyperresponsiveness is determine the provocative concentration of
the inhaled agent that causes a fall of 20% in FEV1 (PC20 FEV1) (157). Compared to
measuring fluctuation of peak flow, measuring blood eosinophil count or reversibility to
inhaled $\beta_2$ agonist measuring PC20 methacholine was shown to have the higher
accuracy to make a correct diagnosis in mild to moderate asthma (158). Methacholine or
histamine bronchial responsiveness is mainly seen as a marker of airway wall
remodelling or intrinsic smooth muscle abnormality (159). The role of eosinophilic
inflammation in bronchial hyperresponsiveness, though not absent, is limited (160).

Indirect challenges such as mannitol or exercise challenge are complementary
to direct agent challenges and may reflect more accurately the underlying airway
inflammation (161). Direct challenge tests are sensitive and better to exclude asthma,
while indirect challenge tests are seen as more specific and better to confirm the
presence of the condition (162).

The level of bronchial hyperresponsiveness to indirect agents is highly and
rapidly sensitive to ICS treatment (161). The effect of ICS on responsiveness to
histamine and methacholine is much less impressive but sustained decrease over time was observed with continuous treatment (159). Some study suggests that looking at FVC rather than FEV1 during a methacholine challenge may more informative on disease severity (163). The slope dose response curve to methacholine was shown to correlate to ACQ in a population of unselected asthmatic patients, the stronger the responsiveness the poorer the asthma control (164).

The utility to include bronchial hyperresponsiveness (BHR) as a parameter to adjust asthma treatment has been less studied than with FeNO. There is one study that showed that monitoring methacholine responsiveness by using PC20M in order to adjust the dose of ICS improved asthma control (165). Although another study could not find any difference in terms of asthma-free days; however, adjustment by BHR produced a better outcome with respect to pre-bronchodilator FEV1 in allergic asthmatic children (166).

Most of asthmatics are seen in the primary care setting. As asthma diagnosis is difficult in primary care and often leads to over-diagnosis (167,168) and wrong treatment allocation, it is an urgent need to find a convenient test for assessing bronchial hyperresponsiveness that may be applicable for general practitioners i.e. easy to learn and administer and not too time-consuming. Mannitol challenge might do it but it has to be demonstrated in large scale study in general practice (169).

4. Asthma prediction

Although some previous papers (170) looked for early markers for future asthma, the first index built on a prospective cohort of newborn children was the Asthma Predictive Index (API) (2). Several indicators were used to use a loose and a stringent index which included major and minor criteria. These indices were used to predict asthma at the age 6, 8, 11 and 13 years. API was modified to be used as an
inclusion criteria tool in the Prevention of Early Asthma in Kids (PEAK) study as an expert opinion: one minor criterion (recurrent nasal symptoms) was substituted for two (sensitization to aeroallergens and food allergy) (171).

The Isle of Wight score (172) predicted persistence of wheeze at age 10 of children who wheezed at 1, 2 and 4 years of life (see table 3 for specific items of the score, range 0-4). A cut-off point of ≥ 3 was found to be the highest discriminative.

Another predictive score was developed from the data of a nested case-control study of 449 children included in the Environmental and Childhood Asthma birth cohort (ECA) (173) (4). Children with recurrent [≥2 episodes of or ≥4 weeks (persistent)] doctor confirmed bronchial obstruction by their second birthday were cases. The authors built a severity score (0-12 points, see table 3 for items in the score) and used a cut-off of >5 to predict asthma at age 10.

The PIAMA (Prevention and Incidence of asthma and Mite Allergy) score (174) was calculated from the findings of this birth cohort by the age of 8 years. Several markers found in children who had wheeze and/or cough at night without colds during the previous 12 months at ages 1 through 4 years were used to build a score (0-55 points) in order to predict asthma at age 8 years. A cut-off value of ≥ 20 was found to be the best in diagnostic performance.

The latest predictive model published is the one from the Leicestershire Respiratory Cohort Studies (175), which included children followed from birth who had at least a health care visit between ages 1 and 3 years for respiratory problems plus wheeze and/or cough without a cold and/or cough at night. The presence of wheeze plus asthma medication during the previous 12 months was used as asthma case definition at 6-8 years of age.
Although those prediction tools are easy to apply their diagnostic power needs to be improved: the best Youden’s index does not reach even 0.5, and although the specificity value is quite acceptable, the sensitivity one is quite low. Performance of API and PIAMA scores in subsequent (validation) studies did not improve, producing relatively low rates of false positives (8%-67%) but quite high rates of false negatives (29-80%) (174,176-178).

An additional limitation which has not been fully addressed is the exact definition of the dependent (outcome) variable used to diagnose asthma at the age when the condition is intended to be predicted. Different definitions may have important effects on the predictive probabilities as provided by the predictive model (179). However, and based on the data in table 3, there seem to be two different areas which might determine future asthma when present in infants or preschool children: allergy and severity of wheezing episodes.

Other attempts to build prediction indexes/scores to predict asthma in adulthood from data in childhood have reached to similar conclusions (180). Some authors have suggested that biological markers might predict asthma. Among those biomarkers which might have some usefulness are: eosinophils, ECP, specific IgE, filaggrin mutations, TH2 interleukins, FeNO, EBC characteristics and composition and, of course, genetics in the form of polygenic risk and genetic risk scores (181-184).

In order to use prediction indices as a generalised tool, their predictive power needs to be improved. The current evidence suggests that a tool based only on clinical data is limited in its predictive capacity; and that adding one or several biomarkers could be helpful. Which biomarker(s) is(are) more useful remains to be elucidated; and might be a research priority.
There are probably four fields in which the new predicting tools need to be improved: 1) Clarification of the dependent variable (outcome definition); 2) Combination of clinical and biological markers; 3) Application of more sophisticated and available statistical methods; and 4) Uniformity of the population for which the score is developed.

The clarification of the outcome variable is closely related to a better profiling of asthma phenotypes and their stability at certain ages (adolescence and young adulthood). This clarification should not be solely based on the clinical and biological marker classification, but also on the response to the different available treatments.

CONSENSUS EXERCISE

The exercise included two Delphi rounds previous to a summarising workshop in which the information obtained in the Delphi rounds was shared and the three most important topics among those obtaining a mean score of 3 or more in the Delphi rounds were chosen and ranked.

Delphi exercises (1st and 2nd rounds)

In order to reach an agreement on the most important diagnostic tools for future research investment, a list of statements extracted from the review, 21 statements (Table 4) describing the likelihood that further investment in each technique would result in the development of simple, accurate, inexpensive, non-invasive diagnostic tool/s were extracted from the review.

The statements were circulated amongst 37 European asthma experts including health professionals, researchers, people with asthma and industry representatives who were asked to rank the potential impact of research investment in each technique or tool (score 1-5; 1=very low, 5=very high). The e-Delphi exercise was conducted over two rounds: round one (August 2015) 25 responses were collected. Round two (September
2015) respondents from round 1 were asked to review their responses, along with the average score for each statement and asked whether they would change their ranking and given an opportunity to provide any comments, in total 16 responses were obtained from the 25 requests.

Statements with a mean score 3 or more were considered to have acceptable consensus on their likely impact on the investment on asthma diagnosis and/or monitoring. From the list of 21 statements extracted from the review 11 obtained a mean score 3 or more (Table 4).

**Summarising workshop**

In order to better refine and contextualise the priorities produced from the Delphi exercise, and to reach an agreement on those likely to have the biggest impact on people with asthma, a workshop was organised during the 2015 European Respiratory Society meeting on September 26th, 2015. Representatives from the working group, healthcare professionals, researchers, people with asthma, patient organisation representatives and industry representatives, discussed the results from the exercise. Attendees were asked to rank the top three diagnostic tools which should be considered as priorities in the future. The three most impactful diagnostic and or monitoring tools were ranked from highest to lowest, as shown in table 5.

**CONCLUSIONS**

Research on the prediction of asthma in preschool age with reasonable accuracy and how to integrate the new biological markers in the diagnosis and monitoring of asthma should be the two main research areas towards which the economic effort should be addressed. A third area of importance is the measurement of exhaled volatile organic (VOCs) compounds. If Volatilome is contemplated as a new biological marker, the importance of its measurement would be probably enhanced.
The members of the European Asthma Research and Innovation Partnership (EARIP) who participated in one or more stages of the present consensus were:

- Aurora, Paul; University College London; UK.
- Baraldi, Eugenio; University of Padova; Italy.
- Blakey, John; Liverpool School of Tropical Medicine; UK.
- Carraro, Silvia; University of Padova; Italy.
- Compton, Chris; GSK; UK.
- Fleming, Louise; Imperial College; London; UK.
- Fowler, Steve; University of Manchester; UK.
- Gaillard, Erol; University of Leicester; UK.
- Gappa, Monika; Marienhospital Wesel; Wesel; Germany
- Garcia-Marcos, Luis; University of Murcia; Spain.
- Gibson, Frankie; EARIP Patient Advisory Group; UK.
- Glenn Crater, Glenn; Aerocrine; UK.
- Louis, Renaud; University of Liège; Belgium.
- Moreno-Galdo, Antonio; University Hospital Vall d'Hebron; Barcelona; Spain.
- Niven, Rob; University of Manchester; UK.
- Peroni, Diego; University of Pisa; Italy.
- Priftis, Kostas; University of Athens; Greece.
- Roberts, Amanda; EARIP Patient Advisory Group
- Ryan, Dermot; General Practitioner, UK
- Sanchez-Solis, Manuel; University of Murcia; Spain.
- Schuster, Antje; Heinrich-Heine-Universität Düsseldorf; Germany.
- Seppala, Ulla; Aerocrine; UK.
- Usmani, Omar; Imperial College, London; UK.
- van der Schee, Marc; Academic Medical Centre, Amsterdam; The Netherlands.
- van Sont, Jacob; Leiden University Medical School; The Netherlands.
Reference List


99. Saadeh C, Cross B, Saadeh C et al. Retrospective observations on the ability to diagnose and manage patients with asthma through the use of impulse...
oscillometry: comparison with spirometry and overview of the literature. *Pulm Med* 2014;2014:376890-


143. Pellegrino R, Brusasco V. Point: Is an increase in FEV(1) and/or FVC >/= 12% of control and >/= 200 mL the best way to assess positive bronchodilator response? Yes. *Chest* 2014;146:536-537.

144. Hansen JE, Porszasz J. Counterpoint: Is an increase in FEV(1) and/or FVC >/= 12% of control and >/= 200 mL the best way to assess positive bronchodilator response? No. *Chest* 2014;146:538-541.


Table 1. List of topics agreed to be covered by the structured review

- **Diagnostic markers**
  - **Inflammation markers and cells:**
    - Blood
    - Eosinophils
    - Periostin
    - Exhaled breath
    - Exhaled nitric oxide
    - Volatile organic compounds
    - Markers in breath condensate
    - Markers in sputum and bronchoalveolar lavage
    - Systems biology
  - **Lung function tests:**
    - Spirometry
    - Body plethysmography
    - Impulse oscillometry and forced oscillation technique
    - Interrupter technique
    - Infant lung function testing
    - Inert gas washout
    - Bronchodilation
    - Bronchial challenge tests

- **Asthma prediction**
Table 2. Framework applied for each of the topics in the structured review

- What is the current status of the specific diagnostic tool?
  - Please describe very briefly the literature search strategy
  - Is it a useful tool to diagnose/follow up asthma?
  - Should it be part -currently and in the near future- of the diagnosis/follow up of asthma in every case and age?
  - Is it suitable for point of care detections?
  - Will it enable self-evaluation and follow up of patients?

- What the future would be with respect to the specific tool?
  - Do you expect further advances here? If so, which ones?
  - If you expect several advances, please state the one most important in your opinion
Table 3: Summary of prediction tools from birth cohorts

<table>
<thead>
<tr>
<th></th>
<th>API (2)</th>
<th>IoWight (172)</th>
<th>ECA† (173)</th>
<th>PIAMA (174)</th>
<th>Leicester (175)</th>
</tr>
</thead>
<tbody>
<tr>
<td>General characteristics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Children surveyed</td>
<td>1246</td>
<td>1456</td>
<td>449</td>
<td>1921</td>
<td>1226</td>
</tr>
<tr>
<td>Age at assessment (years)</td>
<td>0-3</td>
<td>0-4</td>
<td>0-2</td>
<td>0-4</td>
<td>1-3</td>
</tr>
<tr>
<td>Age at prediction (years)</td>
<td>6-13</td>
<td>10</td>
<td>10</td>
<td>8</td>
<td>6-8</td>
</tr>
<tr>
<td>Outcome prevalence (%)</td>
<td>13.7</td>
<td>37.2</td>
<td>N.A.</td>
<td>11.7</td>
<td>28.1</td>
</tr>
<tr>
<td>Parameters</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Frequency of wheezing episodes</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Wheezing without colds</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Recurrent nasal symptoms</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diagnosis of eczema</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Parental history of asthma</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood eosinophilia</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sensitization to aeroallergens</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recurrent respiratory infections</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duration wheezing of episodes</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hospitalisations due to wheezing</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parental use of inhaled</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>medication</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male gender</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Medium/low parental education</td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Post-term delivery</td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age &gt;1 year</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Activity disturbance</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Shortness of breath</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Exercise-related wheeze/cough</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Aeroallergen related wheeze/cough</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diagnostic performance</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cut-off point</td>
<td>L§</td>
<td>S§</td>
<td>≥3</td>
<td>&gt;5</td>
<td>≥20</td>
</tr>
<tr>
<td>Sensitivity</td>
<td>40</td>
<td>15</td>
<td>53</td>
<td>52</td>
<td>60</td>
</tr>
<tr>
<td>Specificity</td>
<td>80</td>
<td>96</td>
<td>85</td>
<td>88</td>
<td>76</td>
</tr>
<tr>
<td>PPV (%)</td>
<td>27</td>
<td>42</td>
<td>68</td>
<td>54</td>
<td>23</td>
</tr>
<tr>
<td>NPV (%)</td>
<td>88</td>
<td>86</td>
<td>74</td>
<td>87</td>
<td>94</td>
</tr>
<tr>
<td>Youden’s index</td>
<td>0.20</td>
<td>0.11</td>
<td>0.38</td>
<td>0.40</td>
<td>0.36</td>
</tr>
</tbody>
</table>

† Nested case-control study
§ Loose and Stringent indexes at 11 years
Table 4. List of the 21 statements extracted from the review, ranked according to the mean score obtained in the two Delphi rounds.

<table>
<thead>
<tr>
<th>Statement</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Prediction of future asthma in preschool children with reasonable accuracy.</td>
<td>3.67</td>
</tr>
<tr>
<td>2. New biological markers of asthma (e.g. genomics, proteomics and metabolomics) as a tool for diagnosis and/or monitoring.</td>
<td>3.54</td>
</tr>
<tr>
<td>3. New/improved tools to monitor lung function in the clinical setting</td>
<td>3.38</td>
</tr>
<tr>
<td>4. Assessing variability over time as a tool for diagnosis</td>
<td>3.33</td>
</tr>
<tr>
<td>5. FeNO as a tool in the diagnosis of asthma in patients older than 5 years of age.</td>
<td>3.29</td>
</tr>
<tr>
<td>6. Refinement of symptom scores e.g. Asthma Control Test</td>
<td>3.21</td>
</tr>
<tr>
<td>7. Tools to measure volatile organic compounds (VOCs) in exhaled breath condensate</td>
<td>3.17</td>
</tr>
<tr>
<td>8. Exhaled nitric oxide (FeNO) as a tool to guide the adjustment of inhaled corticosteroid dose in primary, secondary and tertiary care.</td>
<td>3.13</td>
</tr>
<tr>
<td>9. Definition of standardised, normal values and cut-offs of lung function tests at any age in EU populations for diagnosis and/or monitoring</td>
<td>3.13</td>
</tr>
<tr>
<td>10. Bronchodilation test as a tool for diagnosis and/or monitoring</td>
<td>3.04</td>
</tr>
<tr>
<td>11. Functional indexes other than FEV₁ (e.g. FVC, FRC, RV or RV/TLC) as a tool for diagnosis and/or monitoring</td>
<td>3.00</td>
</tr>
<tr>
<td>12. Serum periostin as a biomarker of allergic asthma as a tool for diagnosis and/or monitoring</td>
<td>2.92</td>
</tr>
<tr>
<td>13. Assessment of blood eosinophils as a tool for diagnosis and/or monitoring.</td>
<td>2.88</td>
</tr>
<tr>
<td>14. Measurement of ventilation inhomogeneity (multiple breath washout) as a tool for diagnosis and/or monitoring.</td>
<td>2.79</td>
</tr>
<tr>
<td>15. Bronchial challenge/hyperresponsiveness as a tool for diagnosis and/or monitoring.</td>
<td>2.79</td>
</tr>
<tr>
<td>16. Tools to measure oxidative stress markers in exhaled breath condensate</td>
<td>2.75</td>
</tr>
<tr>
<td>17. Tools to measure non-volatile compounds, such as cytokines or chemokines, in exhaled breath condensate.</td>
<td>2.67</td>
</tr>
<tr>
<td>18. The interrupter and forced oscillometry techniques as tools for diagnosis and/or monitoring in non-cooperative children.</td>
<td>2.63</td>
</tr>
<tr>
<td>19. Plethysmography as a tool for diagnosis and/or monitoring.</td>
<td>2.33</td>
</tr>
<tr>
<td>20. Measurement of blood eosinophil cationic protein as a tool for diagnosis and/or monitoring.</td>
<td>2.25</td>
</tr>
<tr>
<td>21. Peak flow variability testing in routine practice as a tool for diagnosis and/or monitoring.</td>
<td>2.08</td>
</tr>
</tbody>
</table>
Table 5. Three most important fields ranked for research investment in tools for diagnosing and/or monitoring asthma (note that lower score means more importance)

<table>
<thead>
<tr>
<th>Statement</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Prediction of future asthma in preschool children with reasonable</td>
<td>1.63</td>
</tr>
<tr>
<td>accuracy</td>
<td></td>
</tr>
<tr>
<td>2. New biological markers of asthma (e.g. genomics, proteomics and</td>
<td>1.69</td>
</tr>
<tr>
<td>metabolomics) as a tool for diagnosis and/or monitoring</td>
<td></td>
</tr>
<tr>
<td>3. Tools to measure volatile organic compounds (VOCs) in exhaled</td>
<td>2.69</td>
</tr>
<tr>
<td>breath condensate</td>
<td></td>
</tr>
</tbody>
</table>
Table S1. Search strategies per topic (for online supplement)

**Blood**: PubMed was searched for terms “asthma diagnosis and blood cells”, “asthma diagnosis and biomarkers”, “asthma monitoring and blood cells”, “asthma monitoring and biomarkers”, “asthma and biomarkers”.

**FeNO**: Pubmed and Embase were searched with the following strategy: “Exhaled nitric oxide and asthma and diagnosis”; “Exhaled nitric oxide and asthma and monitoring”.

**VOCs**: Pubmed and Embase with the following search strategies: “Volatile organic compounds AND asthma AND diagnosis”; and “Volatile organic compounds AND asthma AND monitoring”.

**Breath condensate**: Pubmed and Embase was searched with the following search terms: “exhaled breath condensate”, “condensate” AND “asthma diagnosis”, “asthma monitoring”. Search limits: “English”.


**Systems biology**: Pubmed and Embase was searched with search terms “system biology”, “metabolomics”, “proteomics” AND “asthma diagnosis”, “asthma monitoring”. Search limits: ‘English’

**Spirometry and plethysmography**: Pubmed was searched with search terms “Asthma AND diagnosis AND spirometry”, and “asthma AND diagnosis AND plethysmography”. Also, a secondary search was done, selecting articles from references.

**LFT in non-cooperative patients**: Pubmed was searched using as key words “lung function tests”, “lung function evaluation”, “pre-school children”, “asthma”, “bronchial reversibility”, “forced oscillation technique”, “interrupter technique”, using as search limit “English”.

**Infant lung function tests**: Pubmed was searched with search terms ‘Infant lung function’, ‘infant pulmonary function’, AND ‘asthma’, asthma phenotypes’. Search limits: ‘ages: birth to 23 months.

**Washout**: Pubmed was searched with the terms (asthma OR wheeze) AND (inert gas washout OR multiple breath washout OR multi-breath washout OR single breath
Eighty-eight publications were identified, of which 18 are cited here. Four further publications were identified from review of the first tranche.

**Bronchodilation:** Pubmed and Embase with the following search strategies: “Broncholilation test AND asthma AND diagnosis”; and “Broncholilation test AND asthma AND monitoring”

**Bronchial Challenge tests:** Pubmed and Embase with the following search strategies: “Bronchial challenge test AND asthma AND diagnosis”; and “Bronchial challenge test AND asthma AND monitoring”

**Asthma prediction:** The strategy on asthma prediction was: [(asthma) AND ("predictive index" OR "predictive algorithm" OR "predictive tool" OR "predictive score"))] OR “asthma prediction”. The databases looked in were PubMed, Scopus, Cochrane and Embase with no specific starting date. There was language limitation to English and Spanish and it included only journal articles. The search retrieved a total of 822 papers which were reduced to 688 after discarding duplicates; and further to 107 after selecting those which were directly relevant (not including those only measuring associations of risk factors with future asthma). Of those 108, only 48 were specifically focused on the prediction of new cases of asthma based on risk factors of the family or acting in the first months or years of life. Sixteen of those 48 were reviews or comments on the original papers, and thus the present review is focusing on the remaining 32. The rest of the 108 articles (n=60) were devoted to the prediction of asthma exacerbations (n=44), of a good response to immunotherapy (n=6), of suffering from occupational asthma (n=7) and of case detection in administrative databases (n=3).